UNSPSC 51171806: Metoclopramide

This classification denotes an antiemetic agent with the molecular formula C14H22ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4YEB44I46, chemically known as 2-methoxy-4-amino-5-chloro-n,n-dimethylaminoethyl)benzamide but generally known as metoclopramide, which bears US NIH Compound Identifier 4168. European Medicines Agency schedules Metoclopramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08902MIG. The term METOCLOPRAMIDE is an International Non-Proprietary Name.

UNSPSC 51171806 Metoclopramide is a Commodity code within the pharmaceutical products taxonomy. Recent state and local opportunities tagged under this code do not reflect purchases of metoclopramide itself but rather broader pharmaceutical procurement and drug testing services. Collin County Community Supervision and Corrections Department posted RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026), which encompasses immunoassay screening and confirmation testing but does not specify metoclopramide as a line item. The Texas Health and Human Services Commission issued RFI HHS0017013 (April 3, 2026) seeking vendor input on a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. The issuing bodies span county corrections departments, state health agencies, and cooperative purchasing alliances, indicating that the code sits within a fragmented landscape where state health departments, local criminal justice agencies, and multi-jurisdictional purchasing groups each procure pharmaceutical products and services through separate channels.

Recent activity is concentrated in Texas and Minnesota. The Collin County RFP represents the most concrete pharmaceutical-adjacent opportunity, with an estimated contract value of $600,000 over two years commencing September 1, 2026, and includes three optional one-year renewal periods. The MMCAP RFP does not disclose an award value but covers a two-year initial term with optional extensions through June 30, 2028, and applies across multiple state and local participating entities. The Texas HHS RFI serves as preliminary market intelligence gathering rather than a formal competitive procurement, with no budget identified at that stage. None of the three recent opportunities explicitly names metoclopramide or other specific individual drug products in their scope summaries, suggesting that this Commodity code may not align with the actual procurement activity being conducted under it, or that metoclopramide represents a minor line item within larger multi-drug framework agreements rather than a standalone procurement focus.